VEA
PVLA

Virtus ETF Advisers’s Palvella Therapeutics PVLA Stock Holding History

Virtus ETF Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,112
Closed -$498K – 393
2018
Q3 		$498K Sell
1,112
-795
-42% -$345K 0.05% 125
2018
Q2 		$773K Buy
1,907
+336
+21% +$160K 0.68% 49
2018
Q1 		$857K Buy
1,571
+856
+120% +$530K 0.74% 65
2017
Q4 		$432K Buy
+715
New +$332K 0.54% 46

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Virtus ETF Advisers's PVLA Position: Q4 2018 in Review

Virtus ETF Advisers sold out of Palvella Therapeutics (PVLA) in Q4 2018, closing a stake of 1,112 shares — an estimated $498K sold.

Virtus ETF Advisers first reported a position in PVLA in Q4 2017 and held it in 4 quarters. The position peaked at $857K in Q1 2018. 98 funds tracked by Wall St. Rank hold PVLA as of Q4 2018.

  • Virtus ETF Advisers reported no remaining Palvella Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,112 Palvella Therapeutics shares in Q4 2018, an estimated $498K.
  • Virtus ETF Advisers first reported a position in Palvella Therapeutics in Q4 2017 and held it in 4 quarters.
  • Virtus ETF Advisers's Palvella Therapeutics position peaked at $857K in Q1 2018.
  • 98 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2018.

Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.